



Day 2: Wed 3rd Sept'14

Room: Charter 4

09:10 - 17:00

## **Neuroscience Drug Targets**

Neuroscience is viewed as a challenging area to develop new drugs, however this therapeutic area incorporates some of the most debilitating and lifechanging disorders that impact society. Alzheimer's disease, schizophrenia and depression place a huge and growing burden on those affected, making it critical that pharmaceutical and academic research maintains its effort to develop new and improved therapeutics. This session will describe some of the efforts being made to identify new ways to impact these diseases from a drug target and disease mechanistic perspective. These will include a focus on Alzheimer's disease, identifying novel targets from human genetics, and exploring ion channels among other new approaches for providing innovative ways to create novel therapeutics for CNS disorders.

| CHAIRS : Dirk Beher, Asceneuron, Keith Wafford, Eli Lilly  |   |   |                    |
|--|---|---|--------------------|
| TIME   | SPEAKER   | TITLE   |                    |
| 9:10   | Session Chairs                                  | Introduction and Welcome  |                    |
| 9:15   | Eric Karran,<br>Alzheimer's Research UK         | Drug development in Alzheimer's disease: darkness before the dawn?  | Session<br>Keynote |
| 10:00  | John Atack,<br>University of Sussex             | Academic Drug Discovery: Innovation, Opportunism or An Oxymoron? – The Sussex Experience                  |                    |
| 10:30  | COFFEE BREAK                                    |   |                    |
| 11:00  | David Collier,<br>Lilly                         | Psychiatric genetics  |                    |
| 11:30  | Poster Taster Session                           |   |                    |
| 12:00  | Snapshots                                       |   |                    |
| 12:30  | LUNCH, Exhibition, Posters, Lunchtime Workshops |   |                    |
| 2:00   | Stuart Hughes                                   | Ion channels as neuroscience drug targets   |                    |
| 2:30   | Pam Shaw  | Identification of new therapeutic approaches for neuroprotection in amyotrophic lateral sclerosis (ALS)   |                    |
| 3:00   | Jonathan Ellery,<br>Takeda                      | The use of Backscattering Interferometry to Investigate Positive Allosteric Modulators of the M4 Receptor |                    |
| 3:30   | COFFEE BREAK                                    |   |                    |
| 4:00   | Panel Discussion                                |   |                    |
| 5:00   | Close of Conference / Prizes Charter 1          |   |                    |
| 5:15   |   | CLOSE   |                    |
| Publication date 09/06/14. More detail, abstracts, speaker biogs, etc, are available on our website: www.elrig.org |   |   |                    |